GALT Stock Overview
A clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Galectin Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.25 |
| 52 Week High | US$4.27 |
| 52 Week Low | US$0.73 |
| Beta | 0.83 |
| 1 Month Change | -41.04% |
| 3 Month Change | -53.18% |
| 1 Year Change | -28.16% |
| 3 Year Change | -38.42% |
| 5 Year Change | -56.60% |
| Change since IPO | -89.58% |
Recent News & Updates
Recent updates
Galectin rises as FDA approves to begin human trial of combination immunotherapy in head and neck cancer
Oct 12Galectin Therapeutics GAAP EPS of -$0.16
Aug 15Galectin: Ability To Potentially Target Unmet Medical Need
Jul 11Galectin: Pursuing A Subset In The NASH Space
Jul 01Read This Before Buying Galectin Therapeutics, Inc. (NASDAQ:GALT) Shares
Feb 25
Is Galectin Therapeutics (NASDAQ:GALT) In A Good Position To Deliver On Growth Plans?
Jan 21How Much Of Galectin Therapeutics, Inc. (NASDAQ:GALT) Do Insiders Own?
Dec 09Galectin Therapeutics reports Q3 results
Nov 09Shareholder Returns
| GALT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.6% | -1.8% | 0.7% |
| 1Y | -28.2% | -7.0% | 25.3% |
Return vs Industry: GALT underperformed the US Biotechs industry which returned -7% over the past year.
Return vs Market: GALT underperformed the US Market which returned 25.3% over the past year.
Price Volatility
| GALT volatility | |
|---|---|
| GALT Average Weekly Movement | 20.3% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: GALT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GALT's weekly volatility has increased from 13% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 14 | Joel Lewis | galectintherapeutics.com |
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration.
Galectin Therapeutics Inc. Fundamentals Summary
| GALT fundamental statistics | |
|---|---|
| Market cap | US$80.34m |
| Earnings (TTM) | -US$45.23m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.7x
P/E RatioIs GALT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GALT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$45.23m |
| Earnings | -US$45.23m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.72 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -113.1% |
How did GALT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/16 23:13 |
| End of Day Share Price | 2025/01/16 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Galectin Therapeutics Inc. is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Ascendiant Capital Markets LLC |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Vernon Bernardino | Dawson James Securities |